Evangelos Terpos, Maria Gavriatopoulou, Ioannis Ntanasis-Stathopoulos, Nikolaos Kanellias, Eirini Solia, Panagiotis Malandrakis, Vasiliki Spiliopoulou, Foteini Theodorakakou, Ilias Katsadouros, Magdalini Migkou, Evangelos Eleutherakis Papaiakovou, Despina Fotiou, Helen Vassalou, Efstathios Kastritis, Meletios Dimopoulos. "Hematologist based management of ocular adverse events using the VRA tool in newly-diagnosed myeloma patients, ineligible for ASCT who received belantamab mafodotin plus lenalidomide/dexamethasone: Updated results from the randomized part 2 of bela-rd Study." Blood, 2025. doi:10.1182/blood-2025-4038